NovoCure (FRA:038) FCF Margin % : -7.69% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is NovoCure FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NovoCure's Free Cash Flow for the three months ended in Dec. 2024 was €-11.8 Mil. NovoCure's Revenue for the three months ended in Dec. 2024 was €154.0 Mil. Therefore, NovoCure's FCF Margin % for the quarter that ended in Dec. 2024 was -7.69%.

As of today, NovoCure's current FCF Yield % is -3.73%.

The historical rank and industry rank for NovoCure's FCF Margin % or its related term are showing as below:

FRA:038' s FCF Margin % Range Over the Past 10 Years
Min: -332.93 Med: -7.45 Max: 17.03
Current: -13.6

During the past 12 years, the highest FCF Margin % of NovoCure was 17.03%. The lowest was -332.93%. And the median was -7.45%.

FRA:038's FCF Margin % is ranked worse than
59.09% of 831 companies
in the Medical Devices & Instruments industry
Industry Median: -4.32 vs FRA:038: -13.60

NovoCure FCF Margin % Historical Data

The historical data trend for NovoCure's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure FCF Margin % Chart

NovoCure Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

17.03

10.95

1.75

-19.72

-11.44

NovoCure Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-15.98	-31.30	-8.76	-0.20	-7.69

Competitive Comparison of NovoCure's FCF Margin %

For the Medical Devices subindustry, NovoCure's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovoCure's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's FCF Margin % distribution charts can be found below:

* The bar in red indicates where NovoCure's FCF Margin % falls into.

NovoCure FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

NovoCure's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-66.109	/	577.985
	=	-11.44 %

NovoCure's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-11.836	/	154.009
	=	-7.69 %

NovoCure FCF Margin % Related Terms

Thank you for viewing the detailed overview of NovoCure's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (FRA:038) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

NVCR:USA

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Headlines

No Headlines